Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics (Nasdaq: PRE) and Care Bears, owned by Authentic Brands Group, announced an exclusive 10-year worldwide partnership for family wellness products. The collaboration will introduce Care Bears by IM8, with gummy multivitamins for children and adults targeted for global launch in the first half of 2027, Care Bears' 45th anniversary year.
This is Care Bears' first wellness license under Authentic's ownership. Products are being developed for IM8's direct-to-consumer, subscription and e-commerce channels, alongside pharmacy, grocery, mass-market and club retailers worldwide. Authentic Studios and Authentic Live will support the partnership through content and fan experiences. Prenetics said the children's launch responds to one of the most frequent requests from IM8's community.
Prenetics (NASDAQ: PRE) announced that IM8 entered a 10-year exclusive worldwide partnership with Authentic Brands Group to build Care Bears by IM8. IM8 will be the exclusive operating partner; Prenetics will record all brand revenue and pay Authentic a royalty. Authentic will also become a strategic shareholder in Prenetics.
The company targets a first-half 2027 global launch of gummy multivitamins for children and adults, with plans to expand into confectionery and kids’ snacks and foods. IM8 generated second-quarter 2026 revenue of $45 million, up approximately 359% year over year, and July revenue of $20.9 million. Prenetics raised full-year 2026 revenue guidance to $220 million–$230 million and initiated 2027 IM8 revenue guidance of $400 million or more. Neither outlook includes Care Bears by IM8; the 2027 outlook assumes no revenue from upcoming product launches.
Prenetics Global (Nasdaq: PRE) named Brian J. Rosin to succeed Stephen Lo as chief financial officer, effective December 31, 2026. The board is expected to formalize the appointment on November 12, 2026. Rosin, IM8’s CFO since May 2026, will serve as Prenetics’ CFO-designate through year-end while working alongside Lo.
The company said the succession follows the plan established when Rosin joined. With IM8 representing substantially all of Prenetics’ revenue, the group will have one CFO and will not fill a separate IM8 CFO position. Lo will remain CFO through December 30, 2026, then become a senior advisor. Rosin will lead global finance and continue reporting to CEO Danny Yeung. Prenetics will release third-quarter 2026 results on November 18, with a Stocktwits earnings event at 8:30 a.m. Eastern Time.
Prenetics Global (NASDAQ: PRE), through its IM8 brand, announced a multiyear NBA nutrition partnership covering Australia and Southeast Asia.
IM8 becomes the Official Nutrition Partner of the NBA in Australia and eight Southeast Asian markets: Brunei, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand and Vietnam. The collaboration includes NBA-themed marketing campaigns and fan engagement initiatives across all nine markets. In 2027, IM8 will host a fan activation at NBA House in the region, where attendees can experience the brand firsthand.
Prenetics (NASDAQ: PRE) announced that CEO Danny Yeung and CFO Brian Rosin purchased a combined $1.0 million of ordinary shares in the open market between August 20–25, 2026, within the post‑earnings trading window. Leadership has now cumulatively invested about $3.75 million in company shares since November 2025, with no sales reported.
Yeung bought 24,681 shares for roughly $502,000 and now totals about $1.75 million of personal purchases. Rosin acquired 23,100 shares for roughly $498,000 in his first open‑market buy.
According to Prenetics, Q2 2026 revenue reached $46.5 million, up ~288% year over year, including $45.0 million from IM8, up ~359%. IM8 generated $20.9 million revenue in July, implying a ~$251 million annualized run‑rate, and the company recorded its first month of positive consolidated Adjusted Free Cash Flow, a non‑IFRS metric. Prenetics raised 2026 revenue guidance to $220–230 million and issued 2027 guidance of more than $400 million. Management also highlighted a $1 billion growth financing commitment to IM8 from General Catalyst's Customer Value Fund.
Prenetics (NASDAQ: PRE), parent of premium health and longevity brand IM8, announced a multi-year global partnership with actress and producer Lily Collins, who becomes IM8’s first Global Ambassador from film and television and a shareholder in Prenetics, aligning her financially with the company.
Collins brings more than 33 million social followers and an engagement rate of about 5.9%, significantly above typical large accounts. She will feature across IM8’s global marketing and product initiatives, expanding the brand’s reach to multigenerational, largely female audiences and into broader entertainment culture.
IM8’s flagship Daily Ultimate Essentials has delivered over 57 million servings, ships around 200,000 servings daily, and generates 54% of revenue outside the U.S. Driven by IM8 growth, Prenetics raised FY 2026 revenue guidance to $220–$230 million, initiated FY 2027 guidance of $400+ million, and reported positive consolidated Adjusted Free Cash Flow in July 2026, which it expects to sustain from Q3 2026 onward.
Prenetics (NASDAQ: PRE) reported Q2 2026 total revenue of $46.5 million, an increase of about 288% year over year, in line with guidance of $46–48 million. IM8 revenue reached $45.0 million, up roughly 359% year over year and within guidance of $44–46 million, marking the sixth consecutive record quarter.
According to Prenetics, July was IM8’s strongest month to date with $20.9 million in revenue, implying an annualized run-rate of approximately $251 million. The company raised its FY 2026 IM8 revenue guidance to $220–230 million and initiated FY 2027 IM8 revenue guidance of $400 million+. July was also the first month of positive consolidated Adjusted Free Cash Flow, which Prenetics expects to remain positive for Q3 and beyond. Financials are presented under IFRS, with certain divested businesses classified as discontinued operations and results unaudited.
Prenetics (NASDAQ: PRE), parent of AI-native wellness brand IM8, appointed veteran Wall Street consumer analyst Caroline Levy to its Board of Directors as an independent director. She will also join the Audit, Compensation, and Nominating and Corporate Governance committees.
Levy has over 30 years of experience covering consumer companies, including senior roles at UBS, CLSA and Macquarie, and currently serves on the Board of Celsius Holdings (NASDAQ: CELH). Prenetics also plans to report its Q2 2026 financial results on August 18, 2026, via a live webcast on StockTwits.
Prenetics (NASDAQ: PRE) will report its Q2 2026 financial results for the quarter ended June 30, 2026, before market open on Tuesday, August 18, 2026. Instead of a traditional earnings press release, Prenetics will issue a detailed shareholder letter and an investor deck on its investor relations website.
The company will host a live-streamed earnings event on Stocktwits on August 18, 2026 at 8:30 a.m. Eastern Time, featuring management commentary and Q&A. A replay will be posted on the investor relations site. Prenetics’ management will also participate in multiple investor conferences in August and September 2026 in Boston, New York City and Brooklyn.
Prenetics (NASDAQ: PRE), parent of AI-native wellness brand IM8, has closed a $1 billion growth financing facility with General Catalyst’s Customer Value Fund to support IM8’s marketing spend.
The CVF will fund up to 70% of IM8’s marketing on a monthly cohort basis, in exchange for a capped share of cohort-level income until a fixed multiple of deployed capital is repaid, after which all value reverts to IM8. The structure is non-dilutive, involves no equity or warrants, has no fixed maturity, covenants, or recourse beyond financed cohorts, and will be recorded as a financial liability with returns booked as interest expense.
IM8 has delivered over 50 million servings to date, about 200,000 daily, and generated preliminarily $17 million revenue in June 2026. Prenetics raised 2026 IM8 revenue guidance to $210–220 million and expects IM8 to reach $300 million annualized run-rate by year-end 2026 and exceed $400 million revenue in 2027. Management reports every $1 of customer acquisition spend has returned $1.44 in gross profit across mature cohorts.